润都股份：近日收到国家药品监督管理局签发的关于硝酸异山梨酯《化学原料药上市申请批准通知书》

Core Viewpoint - The approval of isosorbide nitrate by the National Medical Products Administration enhances the product portfolio of the company and positively impacts future operational performance [2] Group 1: Product Approval - The company has received the approval notice for isosorbide nitrate as a chemical raw material drug [2] - This drug is indicated for the long-term treatment of coronary heart disease, prevention of angina pectoris, treatment of persistent angina after myocardial infarction, chronic congestive heart failure, and pulmonary hypertension [2] Group 2: Business Impact - The approval enriches the company's product categories and improves its full industry chain layout [2] - The future operational performance of the company is expected to be positively influenced by this approval [2] Group 3: Market Considerations - Future market sales may be affected by various uncertain factors, including policy environment and market changes [2]